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Abstract
Background: Schistosomiasis remains a major public health problem in endemic countries and is caused by
infections with any one of three primary schistosome species. Although there are no vaccines available to date,
this strategy appears feasible since natural immunity develops in individuals suffering from repeated infection
during a lifetime. Since vaccinations resulting in both Th1- and Th2-type responses have been shown to contribute
to protective immunity, a vaccine formulation with the capacity for stimulating multiple arms of the immune
response will likely be the most effective. Previously we developed partially protective, single Th- and B cell-
epitope-based peptide-DNA dual vaccines (PDDV) (T3-PDDV and B3-PDDV, respectively) capable of eliciting
immune responses against the Schistosoma japonicum 22.6 kDa tegument antigen (Sj22.6) and a 62 kDa fragment
of myosin (Sj62), respectively.
Results: In this study, we developed PDDV cocktails containing multiple epitopes of S. japonicum from Sj22.6, Sj62
and Sj97 antigens by predicting cytotoxic, helper, and B-cell epitopes, and evaluated vaccine potential in vivo.
Results showed that mice immunized with a single-epitope PDDV elicited either Tc, Th, or B cell responses,
respectively, and mice immunized with either the T3- or B3- single-epitope PDDV formulation were partially
protected against infection. However, mice immunized with a multicomponent (3 PDDV components) formulation
elicited variable immune responses that were less immunoprotective than single-epitope PDDV formulations.
Conclusions: Our data show that combining these different antigens did not result in a more effective vaccine
formulation when compared to each component administered individually, and further suggest that immune
interference resulting from immunizations with antigenically distinct vaccine targets may be an important
consideration in the development of multicomponent vaccine preparations.
Background
Schistosomiasis is one of the most important neglected
tropical diseases (NTDs) and remains a major public
health problem in endemic countries [1,2]. Although
schistosomiasis can be treated with praziquantel [3], the
high re-infection rate limits the overall success of che-
motherapy which typically needs to be readministered
multiple times during the first two decades of life [4,5].
Therefore, the development of a safe, effective vaccine
could improve long-term control of schistosomiasis
and improve the efficacy of chemotherapeutic interven-
tions [6-8].
Vaccination with radiation-attenuated cercariae
induced significant levels of resistance to schistosome
challenge via Th1- and Th2-mediated responses in ani-
mal models of disease. However, multiple concerns
regarding this method make it unsuitable for human use
[9,10]. Considerable efforts have been aimed at the iden-
tification of relevant (immunoprotective) schistosome
antigens resulting in the identification of potential vac-
cine targets [6,11,12]. The major challenge in the devel-
opment of anti-schistosome vaccines is to use defined
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that lead to protection. Although the S. japonicum
Sj22.6 [13], Sj62 [14], and Sj97 [15] antigens, which are
all important components of schistosome adult worm
antigens (SWA), have been shown to be promising vac-
cine candidates, other approaches have focused on elicit-
ing specific B-cell and Th-cell responses by identifying
different antigenic determinants in potential vaccine tar-
gets [16,17]. Epitope-based vaccines offer the prospect
of targeted immunity resulting in safer and more effec-
tive antigen-specific immune responses [18]. Previously
we developed partially protective Th-, and B-cell epitope
vaccines derived from the Sj22.6 or Sj62 antigens,
respectively. However, the levels of protection induced
by both vaccines were limited.
In addition, type I CD8
+ T cells (effector CD8
+ T cells),
which produce INF-g, have been proposed to play an
immunoregulatory role during schistosomiasis by dam-
pening immunopathologic type 2 responses [19,20]. Stu-
dies of the Sm28GST vaccine suggest that both CD4
+ and
CD8
+ T cells might contribute to protection. Activation of
Sm28GST-specific CD8
+ T cells produced high levels of
gamma interferon (IFN-g) involved in protective immune
responses, which suggest that CD8
+ T-cell response
induced by an antigen from the extracellular parasite S.
mansoni may protect the mice from infection [21,22].
Currently, there are numerous efforts focused on opti-
mizing schistosome vaccines (and vaccines against other
infectious agents) using multiple-antigen or multiple-
epitope design [23-26]. One strategy consists of design-
ing subunit constructs containing defined B- and T-cell
stimulatory epitopes obtained by genetic engineering or
by chemical synthesis [27,28]. In some experimental
models, anti-repetitive peptide responses have been able
to confer immune protection against infection [29,30].
In this report we used the full-length S. japonicum vac-
cine candidates Sj22.6, Sj62 and Sj97 to generate eight
distinct computer-based eptiopes identified by their
potential for eliciting Tc-, Th-, or B-cell responses,
respectively, using computer-based epitope-predicting
software. All eight epitopes (named C1, C2, C3, B1, B2,
B3, T2 and T3) were synthesized and encapsulated with
the corresponding recombinant eukaryotic plasmid DNA
encoding the corresponding epitope, respectively, to con-
struct a peptide-DNA dual vaccine (PDDV) that has an
antigenic peptide “shell” and a plasmid “nuclei”.T h e s e
pseudotype virus-like particles have revealed tremendous
potential as novel delivery systems to enhance cell-speci-
fic gene delivery [31,32] and efficiently stimulate the host
immune reponses [33,34]. We examined whether multi-
component PDDVs consisting of Tc (C)-, Th (T)- and B-
cell (B) epitopes were more effective formulations against
S. japonicum challenge than T- or B-cell single-epitope
PDDVs. Our data showed that vaccination of mice with
single-epitope-PDDV elicited corresponding immune
responses - i.e., cytotoxicity, proliferation, or antibody
production, respectively - and that vaccination with T3-
or B3-PDDV induced partial protection. However, vacci-
nation of mice with multicomponent PDDV formulations
comprised of multiple epitopes produced variable
immune responses that failed to induce better protection
than T3- or B3- single-epitope PDDVs.
Results
Epitopes and their encoding DNA sequences
As shown in Table 1, eight candidate epitopes (C1, C2,
C3, T2, T3, B1, B2, and B3), plus an 18K tail respec-
tively, were chosen based on their predicted antigenicity
scores for the further examination of various anti-S.
japonicum immune responses. The DNA sequences
used to encode the respective S. japonicum epitopes
were designed based on the published S. japonicum
DNA sequences for Sj22.6 [13], Sj62 [14] and Sj97 [15].
C2- and C3-PDDV induced the cytotoxic effect and
elicited antibody and IFN-g production in C57BL/6 mice
Cytotoxic responses to epitopes predicted to elicit Tc
responses were measured by immunizing mice with
either C1-PDDV, C2-PDDV, or C3-PDDV. Control mice
were immunized with either 18K-PDDV or PBS. Spleno-
cytes harvested from immunized mice demonstrated
that C2- and C3-PDDV immunizations elicited the
strongest cytotoxic responses (Figure 1A). A significant
IgG response was elicited by C2- and C3-PDDV (but
not C1-PDDV or controls), and C2-PDDV-immunized
mice also developed a significantly elevated IgG2a
response. However IgG1 responses were not observed in
mice immunized with any of the CTL-PDDV formula-
tions (Figure 1B). Analysis of IFN-g (Figure 1C) and
IL-4 (Figure 1D) production of cultured splenocytes from
PBS, control 18K PDDV, C1-, C2-, or C3-PDDV vacci-
n a t e dm i c ed i dn o tr e v e a ls i g nificant increases in IL-4
production. However, following restimulation with the
respective C2- or C3-18K fusion peptide, a statistically
significant increase in IFN-g production was observed
compared to controls restimulated with medium or 18K
in vitro. These results indicate that C2- and C3-PDDV
vaccination induced cytotoxic responses associated with
IFN-g production and IgG and IgG2a production.
T3-PDDV induced both cellular and humoral immune
responses in C57BL/6 mice
To examine the immune responses induced by the
T-PDDVs vaccination, both cellular and humoral immune
responses were analyzed after the final vaccination. Only
splenocytes harvested from T3-PDDV-vaccinated mice
proliferated in response to T3-18K fusion peptide stimula-
tion in comparison to 18K-peptide or medium stimulated
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mice produced significant levels of IFN-g in the absence of
in vitro restimulation with T2- or T3-18K fusion peptide,
suggesting that T2 and T3-PDDV vaccination induced spe-
cific Th1-type cellular immune responses in vivo. However,
in vitro restimulation of splenocytes harvested from T3-
PDDV-vaccinated mice with T3-18K fusion peptide
resulted in a significant increase of IFN-g production
(Figure 2B). T3-PDDV-immunized mice also developed a
significant IL-4 response following in vitro restimulation
with the T3-18K fusion peptide, suggesting that T3-PDDV
could also induce the production of a Th2-associated cyto-
kine (Figure 2C). Compared to both control groups, only
T3-PDDV-immunized mice developed significant antigen-
specific IgG, IgG1, and IgG2a responses (Figure 2D). These
results suggest that immunization with T3-PDDV induced
both Th1/Th2 and antibody responses in C57BL/6 mice.
B3-PDDV induced the highest antibody response in
C57BL/6 mice
To investigate the immune responses induced following
immunization with the B-PDDV epitopes, mice were
immunized with either B1-, B2- or B3-PDDV or the
18K-PDDV or PBS, respectively. Compared to the both
18K-PDDV and PBS control groups, all three B-PDDV
groups developed significantly increased IgG responses.
However, only B3-PDDV-immunized mice developed a
significant IgG1 response (Figure 3A). Furthermore,
only splenocytes harvested from B3-PDDV-immunized
mice proliferated significantly in response to in vitro sti-
mulation with the B3-18K fusion peptide (Figure 3B).
Cytokine production analysis of supernatants showed
that none of the B-PDDVs elicited significant increases
in IFN-g or IL-4 production (Figure 3C and 3D) sug-
gesting that these epitopes mainly elicited significant
changes in antibody production.
Cytokine and antibody responses in mice vaccinated with
CTL-, T- and B-PDDV cocktails
Previous studies have shown that CD8
+ cells play a reg-
ulatory role in schistosomiasis through the regulation of
cytokines, affecting the immune response and immune
pathology [19]. To test whether the CTL-PDDV-induced
CD8
+ T cells were able to improve the immune
Table 1 Design of peptides used in the construction of the PDDVs
Code Amino acid sequence of 18 Lys and the 18 Lys
fused epitopes synthesized for PDDV
formulations
Oligonucleotide sequences used for plasmid
construction
Source Epitope
type
18K KKKKKKKKKKKKKKKKKK None None None
C1 KKKKKKKKKKKKKKKKKKNLMKENKNL 5’-tcgacatgaatcttatgaaagaaaataagaatttag-3’ Sj 97
(555-563)
CTL
5’-aattctaaattcttattttctttcataagattcatg-3’
C2 KKKKKKKKKKKKKKKKKKVRAVANDLK 5’-tcgacatggtaagagcggtggcaaatgacttaaaag-3’ Sj 22.6
(134-142)
CTL
5’-aattcttttaagtcatttgccaccgctcttaccatg-3’
C3 KKKKKKKKKKKKKKKKKKATRLNNEVL 5’-tcgacatggcaactagattgaataatgaagttttgg-3’ Sj 97
(672-680)
CTL
5’-aattccaaaacttcattattcaatctagttgccatg-3’
T2 KKKKKKKKKKKKKKKKKKITELEDVAERERLKA 5’-tcgacatgatcactgaacttgaagatgttgcagag
agagaacgattaaaagcgg-3’
Sj 97
(313-327)
Th-cell
5’-aattccgcttttaatcgttctctctctgc
aacatcttcaagttcagtgatcatg-3’
T3 KKKKKKKKKKKKKKKKKKAKQYNICCKFKELLD 5’-tcgacatggctaagcaatataacatatgttg
taaatttaaagaacttctcgatg-3’
Sj22.6
(111-125)
Th-cell
5’-aattcatcgagaagttctttaaatttac
aacatatgttatattgcttagccatg-3’
B1 KKKKKKKKKKKKKKKKKKEQRLRERDEELESLRKSTTRTI 5’-tcgacatggaacagagacttagagaaagagatgaag
aattagaaagtctaagaaagagtacaactagaacaatattg-3’
Sj 97
(489-510)
B-cell
5’-aattcaatattgttctagttgtcatctttcttagactttcta
attcttcatctctttctctaagtctctgttccatg-3’
B2 KKKKKKKKKKKKKKKKKKWEVRREKEELKKDKEGKVSTL 5’-tcgacatgtgggaagtccgtcgtgaaaaggaagaatt
aaagaaagacaaggaaggcaaagtatccacacttg-3’
Sj 22.6
(77-97)
B-cell
5’-aattcaagtgtggatactttgccttccttgtctttctttaa
ttcttccttttcacgacggacttcccacatg-3’
B3 KKKKKKKKKKKKKKKKKKRQEEEMKKAAEELAKLKEEFEK 5’-tcgacatgcgtcaggaagaagaaatgaagaaagcagccgaa
gaattagctaaactaaaagaagaatttgaaaaag-3’
Sj 62
(167-188)
B-cell
5’-aattctttttcaaattcttcttttagtttagctaattcttcggct
gctttcttcatttcttcttcctgacgcatg-3’
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investigate whether the multicomponent PDDV formu-
lations could result in better immune effection, mice
were immunized with multicomponent PDDV prepara-
tions containing three different types of single PDDVs
at a 1:1:1 ratio, and the levels of cytokines in culture
supernatants and antibodies in sera of vaccinated mice
were measured. C1 and T2-PDDV were not selected for
further study because of their poor immune responses
in above studies, only C2, C3, T3, and B-PDDVs were
used. As shown in Figure 4A, mice vaccinated with
equal concentrations of different PDDV formulations
revealed that IFN-g production was statistically elevated
in the C3-T3-B2 and C3-T3-B3-vaccinated groups fol-
lowing restimulation in vitro with SWA containing
Sj22.6, Sj62, and Sj97 proteins (Figure 4A). In contrast,
IL-4 levels were statistically elevated in mice vaccinated
with C2-T3-B2 following SWA in vitro restimulation
(Figure 4B). Compared to the both 18K-PDDV and PBS
control groups, only C2-T3-B2 and C3-T3-B2 groups
induced significantly increased IgG responses (Figure 4C).
However, only C2-T3-B2-immunized mice developed a
significant IgG1 response (Figure 4D), with IgG2a
antibody only elicited in the C3-T3-B2 group (Figure 4E).
These data suggest that different epitope combinations
favore different cytokine and antibody subclass production
profiles, highlighting the importance of selecting the
appropriate antigen combination for the induction of the
immune responses most likely to elicit protective
immunity.
PDDV cocktails did not improve the resistance to S.
japonicum infection
T h ep r o t e c t i v ee f f e c tc o n f e r r e db yt h ed i f f e r e n tP D D V
or PDDV multicomponent formulations was determined
by quantifying worm and egg (liver) burdens in the
respective vaccination/infection groups (Table 2). Con-
sistent with results described previously by our group
[13,14], T3- and B3-PDDV vaccinations induced signifi-
cant reductions in worm and egg burdens in this experi-
ment. Vaccination with T3-PDDV resulted in a 35.80%
worm burden reduction and a 51.60% egg (liver)
Figure 1 CTL-PDDVs induced the cytotoxicity effect and produced antibody. (A) Effect of C-PDDV vaccination on cytotoxicity. Seven days
after the last C-PDDV, 18K-PDDV, or PBS immunization epitope-specific cytotoxic activity was measured by incubating murine spleen effector
cells or p815 target cells with either C1-, C2-, or C3-18K fusion peptides, 18K control peptide, or medium only, then mixed cells at E:T rations
ranging from 1:10 to 1:100. The CTL activity of the cells was tested using Na2[
51Cr]O4 assay. Data are expressed as the mean ± SD (n = 6 per
group) of 18 mice from three independent experiments performed in triplicate wells. (B) Serum antibody subtype profile following C-PDDV
vaccination. Whole IgG, IgG1, and IgG2a responses to SWA (0.1 mg/ml) following vaccination with C-PDDV formulations, or controls were
measured by ELISA. Data are expressed as the mean ± SD (n = 6 per group) of 18 mice from three independent experiments performed in
triplicate wells. * P < 0.05 and ** P < 0.01, compared to the 18K-PDDV and PBS groups. (C-D) Cytokine profile analysis following C-PDDV
vaccination. IFN-g (C) and IL-4 (D) production of splenocytes harvested from every vaccination group were determined by culturing in triplicate.
In 96-well plates, 10
6cells/well were cultured for 48 h in 200 μl of media in the presence of C1-, C2-, C3-18K fusion peptide (10 μg/ml), 18K (10
μg/ml), or media alone. Supernatants were collected after 48 h of culture for cytokine detection. Bars show the mean ± SD (n = 6 per group) of
18 mice from three independent experiments performed in triplicate wells.
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Similarly, vaccination with B3-PDDV resulted in a
19.10% worm reduction and a 29.20% egg (liver) reduc-
tion compared to the 18K-PDDV-vaccinated controls.
Meanwhile, only mice immunized with C3-T3-B2 were
partially protected (more th a n1 0 %p r o t e c t i o ni nb o t h
worm and egg reductions compared to controls). How-
ever, the data suggests that multicomponent formula-
tions (using the epitopes described) failed to improve
t h er e s i s t a n c et oS. japonicum infection compared to
single epitope (T3 or B3) PDDV vaccination.
Histopathology of egg granulomas in mice livers
Based on the protection results described above, we selected
the vaccination groups with highest egg reductions for mice
liver histologic examination. Compared to both control
groups, the average number of egg granulomas in 10 ran-
dom fields after the challenge infection was significantly
decreased in the livers of mice immunized mice with T3-
PDDV or with the C3-T3-B2 PDDV preparation
(Figure 5A). In addition, the mean-area of non-confluent
granulomas in these livers was statistically smaller in T3-
PDDV-vaccinated mice. These data suggest that
immunization with the T3-PDDV or C3-T3-B2 PDDV
reduced the number and/or size of egg granulomas (Figure
5B).
Discussion
The development of vaccines for complex parasites such
as schistosomes is a great challenge. Vaccination with
radiation-attenuated cercariae induces significant levels
of resistance to schistosome challenge and suggests the
fact that vaccination induced both B and T cell
responses are critical, and combination of different anti-
gens may be an efficient strategy to improve the immu-
noprotection against schistosome infection. In this
study, different schistosome vaccine candidates (alone or
mixed) that stimulated either B or T cell immunity were
tested in a mouse model of disease. Results showed that
combining different antigens in fact did not result in a
more effective vaccine formulation when compared to
each component administered individually, suggesting
that mixed antigens may not be necessary for protection
against schistosome infections and that immune inter-
ference resulting from the inoculation with multiple
Figure 2 T3-PDDV induced both cellular and humoral immune responses. (A) T-PDDV induced cellular immunity. Seven days after the last
immunization with T-PDDVs, 18K-PDDV, or PBS, splenocytes were harvested and antigen-specific proliferation was measured. Splenocytes (2 ×
10
5/well) from each mouse were incubated in triplicate for three days in 200 μl in 96-well plates in the presence of either the T2-18K, T3-18K, or
18K peptides (10 μg/ml), or media alone. To each well 0.5 μCi [
3H] thymidine was added 16 h before the end of the incubation period. Data are
expressed as the mean ± SD (n = 6 per group) of 18 mice from three independent experiments performed in triplicate wells. *** P < 0.001. (B-C)
Cytokine production following T2- or T3-PDDV vaccinations. IFN-g (B) and IL-4 (C) production was measured in splenocytes harvested and
cultured from the respective vaccination groups for 48 h. Bars show the mean ± SD (n = 6 per group) of 18 mice from three independent
experiments performed in triplicate wells. * P < 0.05; *** P < 0.001. (D) IgG, IgG1, and IgG2a responses in immunized mice. Antibody responses
to SWA (0.1 mg/ml) were determined by ELISA. *** P < 0.001, compared with 18K-PDDV and PBS groups. Data are expressed as the mean ± SD
(n = 6 per group) of 18 mice from three independent experiments performed in triplicate wells.
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pected lack of increased protection.
Many years devoted to studying the interactions
between schistosome infection and the resulting immune
responses by hosts has led to the identification of mechan-
isms believed to play a critical role in protective immunity.
Studies have shown that protection elicited by vaccination
is not dependent on one immune mechanism but is multi-
factorial, involving both cellular and humoral elements
and can be affected by the host’s genetic background and
the vaccine regimen [35,36]. Therefore, to improve anti-
schistosome immunity and protection against infection
conferred by respective vaccine formulations, various stra-
tegies including multiple antigenic peptides (MAPs), i.e.
sequential arrangement of epitopes into a single polypep-
tide and multicomponent formulations, have been tested
[17,23,24]. These vaccination modalities have been tested
in animal models and some formulations have proved suc-
cessful [37,38], suggesting that multicomponent formula-
tions can be used to develop effective anti-schistosome
vaccines. Recently, we demonstrated that vaccination with
PDDV based on a T cell-epitope (P5, in this study named
T3) derived from the Sj22.6 tegument antigen or a B cell-
epitope (B3) derived from the Sj62 myosin sequence all
induced partial protection against S. japonicum challenge
in mice [13,14]. In this study we predicted and selected six
additional peptide epitopes derived from full-length Sj22.6,
Sj62, and Sj97 antigens shown to have the potential of eli-
citing protective immunity in various other studies
[6,13,14,39-42]. The experiments were aimed at improving
the immunoreactivity and protective efficacy of the pep-
tide-based approach by comparing immune responses fol-
lowing vaccinations with either single or multicomponent
formulations in mice subsequently infected with S. japoni-
cum. Results from mice vaccinated with Tc-, Th-, or B-
PDDV single-epitope formulations showed that not every
single-epitope PDDV elicits corresponding cytotoxic, T
helper or antibody responses. This finding suggests that at
present, computer assisted epitope prediction is not a very
effective way of generating epitopes and experimental vali-
dation must remain an early step in any vaccine study.
In contrast to the immune response induced by single
PDDVs, cytokine release and antibody production
induced by multicomponent PDDV formulations
showed varied immune response profiles and variability
in protective immunity conferred following vaccination
with multicomponent formulations was not always more
effective than that observed in mice immunized with
single component PDDV preparations. For example,
among multicomponent PDDV formulations, only C2-
Figure 3 B3-PDDV induced the highest antibody response. (A) Analysis of B-PDDV-induced antibody responses. Seven days after the last
immunization with B-PDDVs, 18K-PDDV, or PBS, mouse whole IgG, IgG1, and IgG2a antibody responses to SWA (0.1 mg/ml) were analyzed by
ELISA. Data are expressed as the mean ± SD (n = 6 per group) of 18 mice from three independent experiments performed in triplicate wells. **
P < 0.01 and *** P < 0.001, compared to the 18K-PDDV and PBS groups. (B) Splenocyte proliferation assay. Splenocytes (2 × 10
5/well) from each
mouse were incubated in triplicate wells for three days in 200 μl of media in 96-well plates in the presence of B1-, B2-, B3-18K fusion peptide, or
18K (10 μg/ml) peptides (or media alone). Proliferation was determined by measuring [
3H] thymidine incorporation for the last 16 h of the
experiment. Data are expressed as the mean ± SD (n = 6 per group) of 18 mice from three independent experiments. * P < 0.05. (C-D) Cytokine
production analysis. Supernatants were collected after 48 h of culture and examined for IFN-g (C) or IL-4 (D). Bars show the mean ± SD (n = 6
per group) of 18 mice from three independent experiments performed in triplicate wells.
Wang et al. Parasites & Vectors 2010, 3:109
http://www.parasitesandvectors.com/content/3/1/109
Page 6 of 12T3-B2, C3-T3-B2, and C3-T3-B3-immunized mice
induced partial protection in reducing worm or egg bur-
dens, but all multicomponent PDDV formulations con-
taining T3- or B3-PDDV were not more effective in
reducing worm and egg burdens nor did multicompo-
nent formulations elicit significant changes in cytokine or
antibody production, when compared to mice immunized
with single formulations of T3- or B3-PDDV. These data
suggest that T3- or B3-PDDV appeared to elicit a protec-
tive response against the parasite, but other epitopes or
multicomponent formulations failed to induce an ade-
quate immune response to improve the protection.
Furthermore, these results also indicate that combina-
tions of different types of antigenic epitopes may result in
immune interference resulting in the development of
inefficient immune responses incapable of conferring
protective immunity [43,44]. Others have shown that
multicomponent vaccines can be more immunogenic and
produce significant anti-parasite activity [45-47]. Simi-
larly, DNA vaccines containing multiple antigens also
contributed to improved protective responses against
Schistosoma. For example, using a DNA vaccine encoding
Sj62, Sj28, Sj23, and Sj14-3-3 induced significant Th1-
type cellular responses and conferred partial protection
against S. japonicum infection [48]. However, others have
also reported different results in relation to multicompo-
nent formulations e.g., a multicomponent vaccine based
on antigenic epitopes derived from SmTPI, Sm28, Sm97,
Sm23, and Smcalpain of S. mansoni did not elicit a
response capable of parasite killing in vivo [49]. Several
Figure 4 Cytokines and antibodies responses in mice vaccinated with CTL-, T-, and B-PDDV cocktails. (A-B) Cytokine responses following
vaccination with C-, T- and B-PDDV multicomponent formulations. Seven days after the last immunization with either multicomponent PDDV
formulations, 18K-PDDV, or PBS, splenocyte production of IFN-g (A) and IL-4 (B) from each vaccine group was assessed. Splenocytes from each
mouse were cultured (10
6/well) in triplicate for 48 h in the presence or absence of SWA (50 μg/ml). Supernatants were collected after 48 h and
IFN-g and IL-4 production was assessed. The data are expressed as the mean ± SD (n = 6 per group) of 12 mice from two independent
experiments performed in triplicate wells. (C-E) Antibody responses following multicomponent vaccinations. IgG (C), IgG1 (D), and IgG2a (E)
responses to SWA in immunized mice were determined by ELISA. Data are expressed as the mean ± SD (n = 6 per group) of 12 mice from two
independent experiments performed in triplicate wells. *P < 0.05 and ***P < 0.001, compared to the 18K-PDDV and PBS groups.
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fic regulatory system [50,51] that selectively controls
immune response (such as IgG antibody production) to
the individual determinants on a complex antigen. These
regulatory responses are commonly believed to regulate
the amount, affinity, and isotype composition of antibody
responses to individual epitopes on complex antigens by
interference [51].
In this study, even though we failed to demonstrate
improved protective efficacy using a multiple compo-
nent-based vaccine strategy, we still derived insights
regarding effective design of S. japonicum vaccines in
two ways. First, predicting epitopes with software alone
is not sufficient. A combination of epitope prediction
and experimental screening is needed. Second, multiple
epitope vaccines capable of inducing protective antibody
and cell mediated immune responses against different
schistosomal developmental stages theoretically may be
more effective, however, the multivalent vaccine con-
struct must be well designed to not suffer the effects of
epitope interference.
Conclusion
In conclusion, we have developed single PDDVs and
multicomponent PDDV anti-S. japonicum formulations.
Our experiments demonstrate that mice immunized
with single PDDV formulations were partially protected
against S. japonicum infection and that mice vaccinated
with multicomponent formulations were not necessarily
better protected against S. japonicum challenge. These
data suggest that immune interference may account for
Table 2 Worm and egg burdens following vaccination
Vaccination
Regimen
Mean worm
count ± SD
Mean liver egg
count ± SD
Worm reduction rate (%) Liver egg reduction rate(%)
Compared to the
PBS group
Compared to the
18K group
Compared to the
PBS group
Compared to the
18K group
C2 31.33 ± 6.66 20900.9 ± 1899.84 -31.3 -34.5 10.08 3.7
C3 24.50 ± 4.23 18558.54 ± 2120.31 -2.5 -5.2 20.16* 14.5
T3 14.50 ± 8.39 10270.27 ± 4357.82 39.33** 35.80** 55.81** 51.60**
B1 23.71 ± 7.18 20308.88 ± 3154.43 0.78 0 12.62 6.5
B2 20.40 ± 6.47 21513.51 ± 4128.92 14.64 12.4 7.44 0.9
B3 18.86 ± 3.35 15366.78 ± 2371.41 22.70* 19.10* 34.81** 29.20*
C2-T3-B1 24.80 ± 6.98 19243.24 ± 2172.86 -3.8 -6.4 17.21 11.4
C2-T3-B2 18.75 ± 1.73 20000.0 ± 2167.85 21.55* 19.5* 13.95 7.9
C2-T3-B3 22.57 ± 7.14 22162.16 ± 4496.31 5.56 3.1 -2.1 4.7
C3-T3-B1 25.75 ± 6.70 18648.65 ± 4105.15 -7.7 -10.5 19.77* 14.1
C3-T3-B2 20.00 ± 6.40 12540.54 ± 4658.24 16.32 14.2 46.05** 42.2**
C3-T3-B3 21.33 ± 2.83 15855.84 ± 4944.18 10.74 8.4 31.78* 27.0*
18K 23.33 ± 6.41 21711.70 ± 3937.61 / / / /
PBS 23.88 ± 7.91 23243.24 ± 4784.20 / / / /
The mean worm/liver egg burdens were calculated using results from sixteen mice from two independent experiments (n = 8). Percent protection in the two
independent experiments was calculated by comparing their results with the results obtained from the 18K-PDDV and PBS groups. Results are expressed as
means ± standard errors. *P < 0.05; **P < 0.01, compared to the worm/liver egg burdens of the 18K-PDDV and PBS vaccination groups.
Figure 5 Histopathology of egg granulomas in the livers. (A) Six
weeks after challenge, mice were sacrificed. After portal perfusion,
livers were dissected and stained with H&E for microscopic
examination. The number of granulomas in the liver of each mouse
was counted in 10 random fields and the data are expressed as the
mean ± SD of 16 mice (8 mice/group) from two independent
experiments. (B) The size of nonconfluent granulomas formed
around a single egg was assessed using a video micrometer. The
data are expressed as the mean ± SD of 16 mice (8 mice/group)
from two independent experiments. *P < 0.05, compared to the
18K-PDDV and PBS groups.
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that care must be taken in the selection of epitopes
identified for vaccine preparations containing multiple
epitopes.
Methods
Animal studies and antigen preparation
Six-week-old C57BL/6 female mice were provided by
the Center of Experimental Animals (Nanjing University,
Nanjing, PR China). Oncomelania hupensis harboring S.
japonicum cercariae (Chinese mainland snail strain)
were purchased from the Jiangsu Institute of Parasitic
Diseases (Wuxi, PR China). All animal experiments
were performed in accordance with the Chinese laws for
animal protection and with permission from the Institu-
tional Review Board. Soluble schistosome worm antigen
(SWA) was prepared as previously described [52].
Identification of antigenic epitopes
Selection of B-cell epitopes was based on predictions
made by the Immune Epitope Database and Analysis
Resource (IEDB; http://epitope2.immuneepitope.org/
home.do) [53] and ProtScale http://www.expasy.org/cgi-
bin/protscale.pl[14,54]. All putative T-cell epitopes were
predicted using GUATIF, TEPITOPE and ANTHI-
WHIN software [13,55]. Briefly, the amino acid
sequences for Sj22.6 (GenBank Accession No:
AAC67308), Sj62 (GenBank Accession No: AAC82332),
and Sj97 (GenBank Accession No: Q05870) were ana-
lyzed by software designed to predict the epitopes and
candidate peptides most likely to elicit Tc-, Th-, or B-
cell responses selected based on their respective predic-
tion scores. The 8 selected epitopes containing an 18
Lys (18K) N-terminal tail (epitope-18K fusion peptides)
were synthesized and an 18K control peptide was also
synthesized and purified (Invitrogen, Shanghai, PR
China). The purity of the peptides determined by mass
spectrometry was >99%. The DNA sequences encoding
each of the 8 identified epitopes were synthesized and
purified based on the published S. japonicum DNA
sequences, respectively, for Sj22.6 (GenBank Accession
No: AF030404), Sj62 (GenBank Accession No:
No. AF039187), and Sj97 (GenBank Accession No:
EU488866) (Invitrogen). SalIa n dEcoRI restriction sites
were included in the primer sequences for cloning
purposes.
Preparation of PDDVs
PDDVs encoding the eight antigenic epitopes were pre-
pared and confirmed as described previously [13,14].
The diagram of PDDV preparation was shown in Addi-
tional file 1. Briefly, the recombinant expression plasmid
pUMVC1-mGM-CSF (a gift from Professor Yuzhang
Wu, Institute of Immunology of the Third Military
Medical University, Chongqing, PR China) was 4423
base pairs (bp) long and contained the cytomegalovirus
(CMV) promoter and the mouse GM-CSF gene. The
two complementary single stranded oligonucleotides
encoding each respective epitope were annealed and
inserted into the pUMVC1-mGM-CSF vector and the
resulting plasmids transformed into Escherichia coli
DH5a grown in Luria Bertani (LB) broth. The recombi-
nant plasmid DNAs were purified using the QIAGEN
Endofree Plasmid Maxi Kit (QIAGEN, Hilden, Ger-
many). Plasmid preparations were resuspended in
ddH2O to a final concentration of 1.5-2.0 mg/ml. Agar-
ose gel electrophoresis confirmed that the plasmid pre-
parations were not contaminated with bacterial genomic
DNA or RNA. Preparation of the PDDVs was performed
by titrating peptide into a solution of DNA containing
10 mM HEPES and 150 mM NaCl as described pre-
viously [13,14]. The cationic poly-lysine in 18K control
peptide or epitope-18K fusion peptide was bound to the
anionic plasmid DNA (containing the sequence of corre-
sponding epitope) through electrostatic interactions and
the peptide-DNA complex (PDDV) was condensed into
nanometric pseudotype virus-like particles. Each PDDV
was adjusted with phosphate buffered saline (PBS, pH
7.4) to 100 μlc o n t a i n i n go f2 8μg of peptide and 10 μg
of plasmid. The PDDV containing either the control
18K or the Tc-, Th-, or B-cell epitope-18K fusion pep-
tide were designated as 18K-PDDV, C-PDDV, T-PDDV
or B-PDDV, respectively. The integrity of the PDDVs
was confirmed using the DNA retardation assay, DNase
I digestion assay and transmission electron microscopy
as described previously [13,14].
Immunization and challenge infection
For immune response characterization, three indepen-
dent experiments were carried out. In each experiment,
C57BL/6 mice (6 mice per group) were injected subcu-
taneously (s.c.) in the back with 100 μl of PBS (control
1), 18K-PDDV (control 2), C-, T-, or B-PDDV per
mouse, respectively. The immunization was repeated
three times at 14-day intervals. One week after the final
vaccination, mice were sacrificed for the characterization
of cellular and humoral immune response.
For vaccination/challenge trial, two independent
experiments were carried out. In each experiment,
C57BL/6 mice were divided into fourteen groups con-
sisting of 14 mice per group. Each mouse was injected
subcutaneously (s.c.) in the back with 100 μlo fP B S
(control 1), 18K-PDDV (control 2), C-, T-, B-PDDV, or
multicomponent PDDV preparations, respectively. The
multicomponent PDDV preparations were prepared by
mixing the single PDDVs at a 1:1:1 ratio (33.3 μl each
of C, T- and B-PDDVs, respectively) consisting of 28 μg
of peptides and 10 μg of plasmids in total. The
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vals. One week after the final vaccination, six mice from
each group were sacrificed for the cytokine and antibody
detection. Two weeks after the final vaccination, the
remaining eight mice from each group were challenged
percutaneously with 40 ± 1 S. japonicum cercariae. Six
weeks later the mice were sacrificed and perfused to deter-
mine worm burdens and the liver egg burdens. Reductions
in worms/liver egg burdens are expressed as a percentage
of the burden recorded in the control groups.
Cytotoxicity assay
Cytotoxicity was determined by a 4 h
5lCr release assay as
described previously [56]. Briefly, spleen cells were har-
vested from PBS, C1-, C2-, C3-PDDV or 18K-PDDV
immunized mice and resuspended at a concentration of 1
×1 0
6/ml in complete 1640 medium (containing 10% FCS,
100 U/ml penicillin, 100 μg/ml streptomycin) containing
10 μg/ml C1-, C2-, C3-18K fusion peptide, 18K control
peptide or medium only. After a five-day incubation at 37°
C, the cells were washed and used as effector cells and 5 ×
10
6 p815 (H-2
d) cells were labeled with 200 μCi Na
2[
51Cr]
O4 for 1 h. After thorough washing, labeled p815 cells
were used as target cells and pulsed with 10 μg/ml C1-,
C2-, C3-18K fusion peptide, 18K control peptide or med-
ium only for 2 h at 37°C, washed and resuspended in com-
plete RPMI 1640 at a concentration of 1 × 10
5/ml. Effector
cells were titrated by serial dilution in U-bottom 96-well
plates at Effector/Target ratios of 100:1, 20:1, 10:1. 1 × 10
4
target cells were added, centrifuged for 30 s at 100 × g and
the Effector-Target-cell mix incubated at 37°C, 5% CO2,
90% humidity for 4 h. After centrifugation at 250 × g for
10 min, 100 μl/well supernatant from respective wells was
removed and CPMs were measured with a gamma counter
(Beckman, Fullerton, USA). The percent specific lysis was
determined using the following equation: 100 × [(experi-
mental release-spontaneous release)/(maximum release-
spontaneous release)], with spontaneous release measured
as the counts obtained from target cells incubated in med-
ium alone, and maximum release determined by the counts
o b t a i n e df r o mt a r g e tc e l l se x p o s e dt o1 %T r i t o nX - 1 0 0 .
Enzyme-linked immunosorbent assay (ELISA)
Serum samples were collected seven days after the last
immunization. Standard ELISAs were performed using
SWA as the antigen source [39,52]. Antibody detection
in the sera of immunized mice was performed as pre-
viously described [13,14]. IFN-g and IL-4 levels in the
supernatants of splenocytes stimulated by antigens from
PBS, 18K-PDDV, C-, T-, B-PDDV, or multicomponent
PDDV immunized mice were measured by ELISA using
the eBioscience ELISA Ready-set-Go kit (eBioscience,
San Diego, USA), according to the manufacturer’s
instructions.
Splenocyte proliferation assay
[
3H] thymidine (
3H-TdR) incorporation was used to
measure splenocyte proliferation. Seven days after the
last immunization, six mice from each group were sacri-
ficed and splenocytes harvested. In 96-well plates, 2 ×
10
5 cells per well were incubated for 72 h in 200 μlo f
complete media in the presence of the respective epi-
tope-18k fusion peptides (10 μg/ml) or the 18K control
(10 μg/ml). After 56 h in culture, [
3H] thymidine (0.5
μCi) (Amersham, Burkinghamshire, UK) was added to
each well. At the end of the incubation period, the cells
were harvested on filters and the incorporated [
3H] thy-
midine counted.
Histopathological examination
After portal perfusion, livers were dissected and imme-
diately fixed in 10% buffered formalin for morphometric
analysis. Liver sections were embedded in paraffin and
stained with hematoxylin and eosin (H&E) for micro-
scopic examination of granulomas at 4× (Olympus,
Tokyo, Japan) following sectioning. The number of
granulomas in the liver of each mouse was counted in
10 random fields. The size of nonconfluent granulomas
formed around single eggs was assessed using a video
micrometer (Olympus, Tokyo, Japan) in accordance
with the manufacturer’s instructions.
Statistical analysis
The statistical analysis was performed using SPSS ver-
sion 10.1 (Statistical Package for Social Sciences, Chi-
cago, IL statistical software). Statistical significance was
determined by Student’s t-test with P <0 . 0 5c o n s i d e r e d
statistically significant.
List of abbreviations
PDDV: peptide-DNA dual vaccine; s.c: subcutaneously; CTL: cytotoxic T
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Additional material
Additional file 1: Schematic diagram of forming a PDDV. A cationic
antigenic peptide containing 18 lysines (18K) and the antigenic epitope
was designed and synthesized. An anionic plasmid containing the DNA
sequence of the corresponding antigenic epitope sequence and mouse
GM-CSF was constructed. The cationic peptides and corresponding
anionic plasmids form virus-like particles through electrostatic
interactions at an appropriate charge ratio of peptide and DNA.
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